Albuquerque, NM – Los Alamos National Laboratory recently launched the New Mexico Lab-Embedded Entrepreneur Program (New Mexico LEEP) in January of 2022. Through this program, entrepreneurs are provided a two-year fellowship that focuses on technical solutions to society’s largest concerns. These solutions, also referred to as “deep tech”, help to combat issues including food production, clean energy, climate change and chronic disease. Following a process of rigorous evaluations from investors, scientists, and industry experts, the three LEEP fellows were picked from a total of 35 applicants for the program. As a leading researcher in the field of Alzheimer’s Disease detection, Dr. Kristina Trujillo, Ph.D., was chosen as a promising innovator to participate in the first cohort along with two other distinguished entrepreneurs.

“New Mexico LEEP presents a unique opportunity for Los Alamos National Laboratory and our community to support deep-tech innovators and entrepreneurs,” said Thom Mason, director of Los Alamos National Laboratory. “We look forward to providing the expertise and resources needed to develop new solutions for key national security challenges.”

Through the NM LEEP Program, innovators are immersed in a training plan to facilitate validation and accelerate advancement of their technology so that they may give customers immediate access to ground-breaking technologies with the potential to solve world problems. This two-year program provides opportunities for interactions and connections with an experienced network of mentors and business resources. The NM LEEP curriculum is tailored to support high-tech business growth; therefore, each fellow is matched with experts in their field and given access to the resources of New Mexico’s national laboratories, seed capital, and connections to a large network of mentors, customers, and investors.

T-Neuro Pharma is an ideal fit for the NMLEEP Program based on the company’s current development of its biomarker technology that will enable early diagnosis of Alzheimer’s Disease – allowing for more effective clinical trials of confirmed AD patients. The company is in the portfolio of the New Mexico Start-Up Factory, which is supported by a strong leadership team focused on mentorship and company development. The New Mexico Start-Up Factory was formed in 2018 and continues to advance novel technologies like TNeuroPharma from the lab to the marketplace.

T-Neuro Pharma is an exemplary model of a New Mexico, biotechnology-based company making strides within the start-up community and the Alzheimer’s biomarker industry.  The company continues to build infrastructure while validating the science behind an innovation that could change the way the world diagnosis Alzheimer’s Disease.

For more information about T-Neuro Pharma, visit www.tneuropharma.com.  For more information about LEEP, visit www.nmleep.com. For more information on the New Mexico Start-Up Factory, please visit www.nmsuf.com.